SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 84 filers reported holding SEELOS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,402 | -82.8% | 56,533 | +11.9% | 0.00% | -88.9% |
| Q2 2023 | $60,348 | +18.5% | 50,500 | -31.5% | 0.01% | +50.0% |
| Q1 2023 | $50,937 | -7.6% | 73,693 | -6.1% | 0.01% | +50.0% |
| Q4 2022 | $55,126 | +67.0% | 78,493 | +47.5% | 0.00% | +100.0% |
| Q1 2022 | $33,000 | -45.0% | 53,200 | +1.9% | 0.00% | -50.0% |
| Q4 2021 | $60,000 | -28.6% | 52,200 | +10.6% | 0.00% | -33.3% |
| Q3 2021 | $84,000 | +7.7% | 47,200 | +34.9% | 0.01% | +20.0% |
| Q2 2021 | $78,000 | -33.3% | 35,000 | +75.0% | 0.01% | -44.4% |
| Q1 2021 | $117,000 | +105.3% | 20,000 | 0.0% | 0.01% | +80.0% |
| Q4 2020 | $57,000 | +216.7% | 20,000 | 0.0% | 0.01% | +150.0% |
| Q3 2020 | $18,000 | -14.3% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $21,000 | +40.0% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $15,000 | -6.2% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $16,000 | +14.3% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $14,000 | -17.6% | 20,000 | +100.0% | 0.00% | -33.3% |
| Q2 2019 | $17,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 508,000 | $249,000 | 0.10% |
| 1492 Capital Management LLC | 150,000 | $74,000 | 0.09% |
| Uniplan Investment Counsel, Inc. | 2,069,121 | $1,014,000 | 0.08% |
| ARDSLEY ADVISORY PARTNERS LP | 70,000 | $34,000 | 0.01% |
| Spark Investment Management LLC | 35,210 | $17,000 | 0.01% |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 191,000 | $94,000 | 0.00% |
| WealthPLAN Partners, LLC | 20,000 | $15,000 | 0.00% |
| Procyon Advisors, LLC | 2,500 | $1,000 | 0.00% |
| Renaissance Technologies | 1,078,379 | $529,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |